ArticleTherapeutic advances in respiratory disease
Patient-reported adverse events and management of antifibrotic therapy in IPF: A multicenter, cross-sectional real-world study.
Article in Therapeutic advances in respiratory disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BackgroundAntifibrotic agents slow disease progression and improve survival in IPF, yet real-life data on their use in Turkey are limited.ObjectivesThis study aimed to compare the side effects of antifibrotics in IPF patients.DesignA cross-sectional survey was conducted in 8 centers across 6 provinces in the Aegean Region.MethodsThere were 470 IPF patients who completed a 30-item face-to-face questionnaire. Adverse events and their management were compared between pirfenidone and nintedanib users.ResultsAmong 470 patients, 50.6% used pirfenidone and 49.4% nintedanib. Overall, 70.6% reported at least one side effect (75.5% nintedanib vs. 66% pirfenidone, p=0.023). Medical treatment was required in 30.9% and dose reduction in 18.9%. The most common side effects were diarrhea (30.6%), appetite loss (24.9%), and nausea (22.3%). Diarrhea (p<0.001) and weight loss (p=0.010) were more frequent with nintedanib, while rash, photosensitivity, and fatigue were more common with pirfenidone (all p<0.001). Nausea, vomiting, appetite loss, and fatigue were more frequently reported in women, and vomiting, anorexia, and rash were more frequently observed in patients with comorbidities.ConclusionAdverse events are frequent in IPF patients receiving antifibrotics. Nintedanib mainly causes gastrointestinal symptoms, whereas pirfenidone leads to skin reactions and fatigue. Female sex and the presence of comorbidities were associated with a higher frequency of certain adverse events. Supportive treatment and dose adjustments are crucial for maintaining adherence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.